Pulmatrix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulmatrix, Inc. on December 17, 2021. The report details the closing of a registered direct offering and announces a proposed reverse stock split to be submitted to stockholders for approval.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or operating margins. The primary financial event reported is the completion of a capital raise:
- Preferred Stock Issued: 6,745.0008 shares of Series A Convertible Preferred Stock.
- Common Warrants Issued: 5,620,834 warrants to purchase common stock.
- Placement Agent Warrants: 730,708 warrants granted to H.C. Wainwright & Co., LLC with an exercise price of $0.75 per share.
Material Changes
The material change reported is the successful closing of the Offering on December 17, 2021, following a securities purchase agreement entered into on December 15, 2021. Additionally, the Company announced a proposal for a reverse stock split, which requires stockholder consideration.
Outlook, Risks, and Management Commentary
Management intends to file a proxy statement regarding the proposed reverse stock split. The filing explicitly states that the press release does not contain all information necessary for investment decisions regarding the split and advises stockholders to await the definitive Proxy Statement. No specific forward-looking guidance on revenue or product milestones is included in this specific filing text.
Investor Verification Checklist
- Verify the terms of the Series A Convertible Preferred Stock, including conversion rates and liquidation preferences, in the definitive offering documents.
- Review the upcoming Proxy Statement for details on the reverse stock split ratio and voting procedures.
- Confirm the total capital raised from the Offering, as the specific purchase price per share is not detailed in this text.
- Monitor Form 4 filings for changes in ownership by directors and executive officers related to the Offering.